Clinical Trials Logo
  1. Home
  2. Oropharynx Cancer
  3. NCT04567082
  4. Details
NCT04567082 Clinical Trial

Proteome- and Methylation Profiles in Oropharyngeal Cancer

Oropharynx Cancer Clinical Trial

— PROMEO  

Official title:
Proteome- and Methylation Profiles in Oropharyngeal Cancer

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04567082
Other study ID # N-20200024
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 25, 2020
Est. completion date January 31, 2024

Study information
Verified date May 2024
Source Aalborg University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This clinical study aims to evaluate proteome- and methylation profiles in saliva in patients with oropharyngeal cancers

Recruitment information / eligibility
Status Completed
Enrollment 45
Est. completion date January 31, 2024
Est. primary completion date January 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Cancer group: Inclusion Criteria: - Written informed consent - Verified oropharyngeal squamous cell carcinoma Exclusion Criteria: - Other active cancer - Uncontrolled comorbidity - Unable to give informed consent Control group: Inclusion Criteria: - Written informed consent - Normal ENT examination Exclusion Criteria: - Active cancer - Uncontrolled comorbidity - Unable to give informed consent

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Examination of saliva
Collection of saliva samples

Locations
Country Name City State
Denmark Department of Otolaryngology - Head and Neck Surgery Aalborg

Sponsors (1)
Lead Sponsor Collaborator
Aalborg University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome
Type Measure Description Time frame Safety issue
Primary Differences in proteome and methylation profiles Differences between cancer- and control group At diagnosis
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Completed NCT00158678 - IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Phase 3
Recruiting NCT06016699 - Immunological Function After Radiation With Either Proton or Photon Therapy
Withdrawn NCT04001413 - Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients Phase 2
Completed NCT03435471 - Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer N/A
Completed NCT05055206 - Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers N/A
Recruiting NCT04359199 - QUantitative Assessment of Swallowing After Radiation (QUASAR)
Recruiting NCT05793151 - Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy N/A
Active, not recruiting NCT02908477 - Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer Phase 3
Active, not recruiting NCT00232960 - Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC N/A
Completed NCT05698667 - Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer N/A
Recruiting NCT05757817 - Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae N/A
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Completed NCT03342378 - PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients
Active, not recruiting NCT03416153 - Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer Phase 2
Terminated NCT01066741 - Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Phase 3
Completed NCT03418792 - Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx N/A
Recruiting NCT06088381 - Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL) Phase 2
Recruiting NCT05686226 - E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers Phase 2